.navbar .collapse { display: block; } .mobile-nav { max-height: none !important; } @media screen and (min-width: 1200px) { .navbar #basic-navbar-nav .navbar-nav { position: static !important; } }

Spotlight

In-person and virtual events just for HCPs

SpecialtySee All >

Breast Cancer
Lung Cancer
Gastrointestinal Cancer
Genitourinary Cancers
Ovarian Cancer
Prostate Cancer
Melanoma & Skin Cancer
MCL
MPN
CAR T-cell Therapy
Chronic Lymphocytic Leukemia
Gynecologic Oncology
Hematologic Oncology
Immuno-Oncology
Multiple Myeloma
Urothelial Cancer

Advertise
About OncLive
Editorial Board
MJH Life Sciences brands
Contact Us
Privacy
Terms & Conditions
Do Not Sell My Information

2 Clarke Drive
Suite 100
Cranbury, NJ 08512

Effective Sequencing of Treatments for pNETs

EP. 1: Pancreatic Neuroendocrine Tumor Diagnosis Challenges

February 28th 2014

EP. 2: Pathologic Classification of Neuroendocrine Tumors

February 28th 2014

EP. 3: Treatment of Neuroendocrine Tumor Liver Metastases

February 28th 2014

EP. 4: Alkylating Agents in Pancreatic Neuroendocrine Tumors

February 28th 2014

EP. 5: Role of Somatostatin Analogs for Patients With pNETs

February 28th 2014

EP. 6: Everolimus in Pancreatic Neuroendocrine Tumors

February 28th 2014

EP. 7: RADIANT-3 Trial: Everolimus for Patients With pNETs

February 28th 2014

EP. 8: Utilizing Everolimus and Sunitinib in pNETs

February 28th 2014

EP. 9: Case Study: Treating Metastatic Pancreatic NETs

February 28th 2014

EP. 10: Treatment Sequencing and Combinations in pNETs

February 28th 2014

EP. 11: Conclusion: Effective Sequencing of Treatments for pNETs

February 28th 2014